High-Power Short-Duration vs Low-Power Long-Duration Ablation for Pulmonary Vein Isolation: A Substudy of the AWARE Randomized Controlled Trial

Authors: Jacqueline Joza MD, MSc.*, Girish M Nair MBBS, MSc.[†], David H Birnie MB ChB[†],

Pablo B Nery MD[†], Calum J Redpath MB ChB, PhD[†], Jean-Francois Sarrazin MD^{††}, Jean

Champagne MD^{††}, Jean-Francois Roux MD^{**}, Charles Dussault MD^{**}, Ratika Parkash MD^{***},

Martin Bernier MD*, Laurence D. Sterns MD^{†††}, John Sapp MD^{***}, Paul Novak MD^{†††}, George

Veenhuyzen MD[‡], Carlos A. Morillo MD[‡], Sheldon M. Singh MD^{‡‡}, Mouhannad M. Sadek,

MD^{‡‡‡}, Mehrdad Golian MD[†], Andres Klein MD[†], Marcio Sturmer MD[¶], Vijay S. Chauhan

MD[¶], Paul Angaran, MD^{¶¶}, Martin S. Green MD[†], Jordan Bernick MSc. [†], George A Wells

 PhD^{\dagger} , Vidal Essebag MD, PhD^{*} , for the AWARE - RCT (Augmented Wide Area

Circumferential Catheter Ablation for Reduction of Atrial Fibrillation Recurrence)

Drs Joza and Nair contributed equally as first authors

Institutional Affiliations:

* McGill University Health Center, Montreal, Quebec, Canada

[†]University of Ottawa Heart Institute, Canada

** CHUS-Sherbrooke, Sherbrooke, Quebec, Canada

*** Queen Elizabeth II Health Sciences, Halifax, Nova Scotia, Canada

^{††} IUCPQ, Quebec, Quebec, Canada

^{†††} Victoria Cardiac Arrhythmia Trials, Victoria, British Columbia, Canada

[‡] Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada

^{‡‡} Sunnybrook Health Sciences Center, Toronto, Ontario, Canada

^{‡‡‡} Southlake Regional Health Centre, Newmarket, Ontario, Canada

- [¶]Hôpital Sacré-Cœur de Montréal, Montréal, Québec, Canada
- " University Health Network, Toronto General Hospital, Toronto, Ontario, Canada
- [¶] St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada

Short Title: High vs Low Power for Pulmonary Vein Isolation

Corresponding Author:	Girish M. Nair, MBBS, MSc., FRCPC, FHRS, FCCS		
	Professor of Medicine		
	H-1285-B, Arrhythmia Service, Division of Cardiology		
	University of Ottawa Heart Institute		
	Ottawa, Ontario, Canada- K1Y 4W7		
E-mail:	gnair@ottawaheart.ca		
Telephone:	1-613-696-7272		
Word Count:	4,087 words		
Keywords: atrial fibrillation, pulmonary vein isolation			

ClinicalTrials.gov Identifier: NCT02150902

Abstract

Background: Pulmonary vein isolations (PVI) are being performed using a high-power, short duration (HPSD) strategy. The purpose of this study was to compare the clinical efficacy and safety outcomes of a HPSD vs low-power long duration (LPLD) approach to PVI in patients with paroxysmal atrial fibrillation (AF).

Methods: Patients were grouped according to a HPSD (\geq 40 W) or LPLD (\leq 35 W) strategy. The primary endpoint was the one-year recurrence of any atrial arrhythmia lasting \geq 30 seconds, detected using three 14-day ambulatory continuous ECG monitoring. Procedural and safety endpoints were also evaluated. The primary analysis were regression models incorporating propensity scores yielding adjusted relative risk (RR_a) and mean difference (MD_a) estimates.

Results: Of the 398 patients included in the AWARE Trial, 173 (43%) underwent HPSD and 225 (57%) LPLD ablation. The distribution of power was 50 W in 75%, 45 W in 20% and 40 W in 5% in the HPSD group, and 35W with 25W on the posterior wall in the LPLD group. The primary outcome was not statistically significant at 30.1% vs 22.2% in HPSD and LPLD group with RR_a 0.77 (95% confidence interval [CI]) 0.55-1.10; p=0.165). The secondary outcome of repeat catheter ablation was not statistically significant at 6.9% and 9.8% (RR_a 1.59 [95% CI 0.77-3.30]; p=0.208) respectively. The incidence of any ECG documented AF during the blanking period was numerically lower in the HPSD group: 1.7% vs 8.0% (RR_a 3.95 [95% CI 1.00-15.61; p=0.049). The total procedure time was significantly shorter in the HPSD group (MD_a 97.5 minutes [95% CI 84.8-110.4)]; p<0.0001) with no difference in adjudicated serious adverse events.

Conclusions: A HPSD strategy was associated with significantly shorter procedural times with similar efficacy in terms of clinical arrhythmia recurrence. Importantly, there was no signal for increased harm with a HPSD strategy.

Non-standard Abbreviations and Acronyms: HPSD: High-Power Short Duration; LPLD: Low-

Power Long Duration; QOL: Quality of Life; WACA: wide area circumferential ablation; PVI:

Pulmonary Vein Isolation; AF: Atrial Fibrillation

Clinical Perspective

What is known:

-The optimal power and duration of ablation lesions to produce durable pulmonary vein isolation remain unclear.

-Nonrandomized studies have suggested clinical efficacy with high-power short duration radiofrequency ablation vs low-power long duration.

What this study adds:

-In this large substudy of the AWARE Trial, a high-power short duration radiofrequency ablation strategy was found to be similarly effective as a low-power long duration strategy with no difference in time to first recurrence of any AF lasting \geq 30 seconds.

-Procedural were substantially reduced with high-power short duration ablation with no significant difference in overall complication rates.

Introduction

Novel ablation techniques for pulmonary vein isolation (PVI) have been of significant interest, but no more so than that of the high-power, short-duration (HPSD) lesion strategy which has seen an incredible uptake among experienced and new operators alike. Its theoretical advantages of a shorter procedure time, increased likelihood of first-pass isolation, theoretically improved safety profile, and ease of applicability have made it an attractive alternative to a standard low-power, long-duration lesion (LPLD) application.

The biophysics profile of HPSD support its use in the atria. In vitro modeling has confirmed a linear relationship between increasing total energy delivery and lesion depth, where the energy delivered is dependent both on power and time (Energy (J) = Power (W) x time (seconds))^{1,2}. However, lesion *width* appears to be larger with HPSD ablation for the same energy delivered because it creates a large zone of direct resistive heating with shorter temperature decay time ³. This has been confirmed in a porcine animal model demonstrating improved lesion-to-lesion uniformity with wider lesions at similar depths as compared to LPLD lesions ⁴. This has translated into higher acute success rates with shorter radiofrequency (RF) time and lower incidence of chronic pulmonary vein (PV) reconnections in observational studies ⁵.

A comparable safety profile to conventional ablation has also been observed across observational studies ⁵⁻⁷. Parameters identifying durable lesion formation with simultaneous lesion safety have been adapted to HPSD. These include predefined impedance drops, loss of local electrograms, unipolar signal modification, and proprietary algorithms such as lesion size index (LSI) and ablation index (AI) ³ both of which include power in its calculation (as opposed to the

Force Time Integral [FTI] which does not). HPSD does not appear to increase the risk of atrioesophageal fistula where appropriate titration of contact force and lesion duration were instituted on the posterior wall ⁸⁻¹⁰. On the contrary, a large observational study suggested a lower rate of atrio-esophageal fistula with HPSD compared to use of 35W on the posterior wall ⁹.

The Standard Versus Augmented Ablation of Paroxysmal Atrial Fibrillation for Reduction of Atrial Fibrillation Recurrence (AWARE) Study (ClinicalTrials.gov Identifier: NCT02150902) randomized 398 patients to receive RF catheter ablation for PVI with either a standard single wide area circumferential ablation (WACA) or an augmented doubled WACA¹¹. In this multicenter Canadian study, approximately half of the Canadian AWARE investigators routinely used a HPSD strategy for PVI. This substudy compares ablation outcomes in patients receiving HPSD as compared to LPLD ablation in the context of a randomized controlled trial.

Methods

The AWARE Trial design and methodology has been previously described ¹². Briefly, 398 symptomatic and drug refractory patients with paroxysmal atrial fibrillation (AF) were randomized to receive radiofrequency catheter ablation for PVI with either a standard single wide area circumferential ablation (WACA) or an augmented double WACA. The hypothesis was that a secondary barrier and wider area of atrial ablation would increase the chance of durable PVI, thereby resulting in reduction of atrial arrhythmias, without affecting procedural safety. The primary outcome was atrial arrhythmia (atrial tachycardia, atrial flutter, or atrial fibrillation ≥ 30

seconds) recurrence between 91- and 365-days post ablation, off antiarrhythmic drugs. Secondary outcomes included need for repeat catheter ablation, procedural and safety variables. Monitoring was performed through use of three 14-day ambulatory continuous ECG monitoring at 3-, 6-, and 12-months post ablation, and three clinical visits. All AF-related hospital visits and any ECG documented atrial arrhythmias during patient encounters were also used for determining the primary outcome.

All patients were randomized after the first WACA lesion set was completed and prior to evaluation of PV isolation. If randomized to the single WACA arm, PV isolation with entrance and exit block was confirmed. After an observation period of 20 minutes, adenosine was given, and subsequent ablation performed as needed. In patients randomized to the double WACA arm, a second lesion set was delivered, followed by a 20-minute observation time after the initial WACA, and then testing for PV bidirectional block. The Biosense Webster Inc. SMARTTOUCH TC or SMARTTOUCH SF ablation catheter were used for ablation. Midway through the trial, the protocol was modified to allow the option of high-power short duration (HPSD) RF delivery.

This AWARE substudy examined trial outcomes based on an operator preferred HPSD or LPLD PVI strategy across 10 centers in Canada. The substudy population included all randomized AWARE patients. HPSD was defined as a power setting of \geq 40 W, and LPLD was defined as a power of \leq 35W. For both HPSD and LPLD effective ablation lesion tags were represented on the electroanatomic map using the VISITAG (Biosense Webster Inc) software with ablation lesions >2mm apart with an interlesion distance (ILD) of 5mm. In the LPLD group, an FTI \geq of 400 g/second (g/s) or an AI of \geq 550 was recommended on the anterior, inferior, and superior aspects

of the PV antra. A maximum power of 25 watts was permitted along the posterior wall of the LA, with a recommended FTI of 300 g/s but not > 400g/s, or a target AI of \geq 400. Operators using the HPSD approach were permitted to use RF energy from 40 to 50 W and energy delivery duration ranging from 5 to 15 seconds during ablation. It was recommended to target a minimum contact force (CF) of 5 g and not to exceed a CF of 20 g during ablation. Ablation lesions delivered on the posterior wall were delivered for shorter duration and/or lower CF and a lower CF and/or duration advised if the catheter tip was close to the esophagus or phrenic nerve. Given the lack of validation of FTI or AI using *high power* settings, lesions did not have prespecified FTI or AI targets.

Data was analyzed according to HPSD or LPLD ablation strategy. Categorical variables were presented as frequencies and percentages, and continuous variables as the mean and standard deviation (SD), as well as median and inter-quartile range (IQR). The two strategies were compared using the standardized difference, with the absolute value of <0.10 indicating a clinically minimal difference¹³. Since the ablation strategies are subgroups of the AWARE Trial, and not determined by randomization an adjusted analysis was needed. The propensity score incorporating all the baseline patient characteristics was computed and the inverse probability treatment weight (IPTW) method using propensity scores was used for all analyses. For the primary outcome of the 1-year recurrence rate of any ECG documented AF, AFI or AT between the two strategies, the Poisson regression model with robust error variances was used and the adjusted relative risk (RR_a) estimate and the corresponding 95% confidence interval (CI) were calculated¹⁴ or the secondary categorical outcomes, a similar analysis plan was followed. For the continuous outcomes, such as procedure duration and fluoroscopy duration, a multiple linear regression model was used for comparing the two strategies, and the adjusted least squares mean difference (MD_a) estimate and

the corresponding 95% CI were calculated. The primary outcome was compared between key subgroups chosen based on clinical relevance (i.e., sex, age, duration of AF, congestive heart failure (CHF), hypertension, diabetes, stroke history, $CHA_2DS_2VAS_c$, WACA (AWARE trial randomization arms single vs double) and based on the test of the ablation strategy by subgroup interaction term in the logistic regression model. The ablation strategies will be compared for all primary and secondary outcomes within the single and double WACA therapy arms. Statistical analysis was performed using SAS software version 9.4 (SAS Institute). The two-sided nominal p-value < 0.05 was considered statistically significant.

The AWARE Trial funding was provided by the Canadian Institutes of Health Research, the University of Ottawa Heart Institute (UOHI) and Biosense Webster Inc., Canada.

RESULTS

Patient Population

Of the 398 patients included in the AWARE Trial, 173 (43%) underwent a HPSD ablation strategy and 225 (57%) a LPLD ablation strategy. The HPSD group consisted of patients with a mean age of 62 years and 40% female, whereas the LPLD group was younger 60 (SD 0.23) with only 28% female (SD 0.26) (Table 1). Other differences included: more hypertension (47% vs 37%, SD 0.21) and diabetes mellitus (12% vs 8%, SD 0.12) in the HPSD group, a higher CHA₂DS₂-VASc score in the HPSD group (1.75 v 1.30, SD 0.35) and less use of baseline anticoagulants medication (78% vs 86%, SD 0.20) and aspirin/antiplatelet agents (6% VS 16%, SD 0.33) and more ARB (20% VS 7%, SD 0.38) in the HPSD group. The HPSD and LPLD groups were similar on other characteristics including: BMI CIED, time since diagnosis, prior history of

stroke/TIAs or thromboembolism, antiarrhythmic drugs (43% in each group), left atrial diameter and LAVI (all SD<0.10). After adjusting for the propensity scores, all absolute standardized differences are < 0.10 indicating similar baseline characteristics when the IPTW are used (Table 1).

Procedural characteristics

In the HPSD group, the distribution of power used on the anterior wall was 50 W in 75%, 45 W in 20%, and 40 W in 5%. The distribution on the posterior wall was 50 W in 70%, 45 watts in 25%, 40 watts in 3% (5 patients), 35 watts in 0.6% (1 patient), and 25 watts in 1.2% (2 patients). The distribution on the roof was 50 watts in 73%, 45 watts in 23%, 40 watts in 2.6% (4 patients), and 25 watts in 0.6% (1 patient). The median lesion duration was 10 sec (IQR 10,10) anteriorly, 8 sec (IQR 7,8) on the posterior wall, and 9 seconds (IQR 8,10) on the roof with an average contact force of 10, 10, and 9 respectively on each location. The power delivery in the LPLD group was limited to 35 W on the anterior, superior, and inferior aspects of the LA antrum, and to a maximum of 25 W at all posterior antral sites. Data on average contact force in the LPLD group was not collected.

Clinical Outcomes

The primary outcome of the 1-year recurrence rate of any ECG documented AF, AFL or AT (symptomatic or asymptomatic lasting \geq 30 seconds) after a blanking period of 90 days occurred in 52 (30.1%) in patients in the HPSD group and 50 (22.2%) in the LPLD group and was not statistically significant (RR_a 0.77 [95% CI, 0.55-1.11]; p=0.165) (Table 2). The secondary arrhythmia outcome of need for repeat catheter ablation because of documented recurrence of

symptomatic arrhythmia trended in favor of the HPSD occurring in 12 (6.9%) of patients compared to 22 (9.8%) in the LPLD group but was not statistically significant (RR_a 1.59 [95% CI, 0.77-3.30]; p=0.208) in the HPSD and LPLD group respectively. Any ECG documented AF (symptomatic or asymptomatic) during the blanking period (within 90 days post procedure) was significantly lower in the HPSD group occurring in 3 (1.7%) patients versus 18 (8%) in the LPLD group (RR_a 3.95 [95% CI, 1.00-5.61]; p=0.049). The presence of an atrial arrhythmia in the blanking period predicting the primary outcome was 67% (3 blanking period arrhythmias predicting 2 primary outcomes) in the HPSD group.

There were no significant differences in secondary health care utilization outcomes or need for emergency department visits or hospitalizations related to a recurrent arrhythmia or from a complication of the procedure itself during the follow-up and blanking periods (Table 2). In a sensitivity analysis examining the use of 45 W vs 50 W in the HPSD group, the primary outcome was not significantly different with 22.9% (8/35) events occurring in the 45 W group vs 33% (42/128) in the 50 W group (RR_a 0.69; 95% CI, 0.36-1.34, p=0.305).

The ablation strategies were compared on the primary outcome across subgroups of sex, age (\leq 65, >65 years), duration of AF (<50, \geq 50 months), CHF, hypertension, diabetes, stroke history and CHA₂DS₂VAS_c (<4, \geq 4), and no significant differences were identified for the ablation strategy by subgroup interaction. (Table 3) The p-values for interaction were all >0.05, except for the duration of AF (p=0.0272) and hypertension (p=0.0291) for which the duration of AF <50 months and no hypertension subgroups had significant reduction in the 1-year recurrence rate.

Procedural Outcomes

The procedural outcomes were all significantly lower in the HPSD group (Table 2). In particular, the mean difference in the total procedure duration was significantly shorter (MD_a 97.5 [95% CI, 84.6 -110.4]; p<0.0001). It is important to note the presence of a mandatory 20-minute waiting time after the entrance and exit block were confirmed with adenosine (single WACA group, and after initial pass, double WACA group). The fluoroscopic exposure time was significantly higher in the LPLD group (MD_a 10.0 [95% CI, 6.7-13.3]; p<0.0001).

Safety Outcomes

There was no significant difference in the rate of adjudicated serious adverse events between the HPSD and LPLD groups (Table 4). Procedural complications included cardiac perforation with tamponade in 2 (0.89%) patients in the LPLD group compared to 0 in the HPSD, major bleeding requiring transfusion in 1 (0.44%) patient with 2 (0.89%) minor bleeding events in the LPLD group compared to 0 in the HPSD group, congestive heart failure in 2 (0.89%) patients in the LPLD group vs 1 (0.58%) in the HPSD, and 1 (0.58%) patient with pulmonary vein stenosis in the HPSD group as compared to 0 in the LPLD group, which occurred in the double WACA group. One perforated esophageal ulcer was noted in the LPLD group which occurred in a chronically immunosuppressed patient on high-dose corticosteroids and a biologic immunosuppressant for nephrotic syndrome. One pseudoaneurysm was noted in each group, and 1 arterio-venous fistula in the LPLD group.

Outcomes of HPSD vs LPLD based on randomization group (single vs double WACA) Single WACA arm

Of the 195 patients included in the single WACA arm of the AWARE trial, 83 (43%) underwent a HPSD ablation strategy and 112 (57%) a LPLD ablation strategy. The primary outcome in the single WACA group was not statistically significant occurring in 28 (39%) of patients in the HPSD group compared to 24 (21%) in the LPLD group (RR_a 0.64 [95% CI 0.39-1.05]; p=0.079) (Table S1). There were numerically fewer patients needing a repeat catheter ablation procedure with 5 (6%) and 14 (12%) patients in the HPSD and LPLD groups respectively (RR_a 2.66 [95% CI 0.94-7.53]; p=0.065). There were smaller numbers of documented asymptomatic or symptomatic AF episodes during the blanking period at 2 (2.4%) versus 12 (10.7%) patients in the HPSD and LPLD groups respectively but the adjusted comparison was not significant (RR_a 3.43 [95% CI 0.69-16.89]; p=0.130). Procedural and fluoroscopic times were significantly shorter in the HPSD arm, MD_a 96.8 ([95% CI 79.3-114.4]; p<0.0001) and MD_a 11.4 ([95% CI (6.65-16.14)]; p<0.0001) respectively.

Double WACA arm

Of the 203 patients included in the double WACA arm of the AWARE trial, 90 (44%) underwent a HPSD ablation strategy and 113 (56%) a LPLD ablation strategy. The primary outcome in the double WACA group was not statistically significant occurring in 24 (27%) and 26 (23%) of patients in the HPSD and LPLD groups respectively ($RR_a 0.97$ [95% CI 0.58-1.61]; p=0.902) (Table S2). The need for repeat catheter ablation was also not significantly different at 7 (7.8%) and 8 (7.1%) in the HPSD and LPLD groups respectively ($RR_a 0.89$ [95% CI 0.31-2.55]; p=0.834). The incidence of documented AF in the blanking period was numerically lower in the HPSD group but did not reach statistical significance 1 (1.1%) vs 6 (5.3%) patients) ($RR_a 6.69$ 95% CI 0.79-55.79]; p=0.080). Procedural and fluoroscopic times were significantly shorter in the

HPSD arm, MD_a 98.2 ([95% CI 79.0-117.3]; p<0.0001) and MD_a 8.5 ([95% CI 3.9-13.2]; p=0.0004) respectively.

DISCUSSION

To our knowledge, this is the largest randomized trial to evaluate patients according to high power short duration vs low power long duration for AF ablation. This substudy reached several important conclusions: 1. A HPSD strategy was found to be similarly effective as a LPLD strategy with no difference in the clinical outcome using a highly sensitive definition of 1-year recurrence of any AF lasting \geq 30 seconds. 2. There was no signal for increased harm with a HPSD strategy, and although there were no statistically significant differences in complication rates, there were numerically higher numbers of tamponades and the presence of a perforated esophageal ulcer in the LPLD group. 3. Procedural and fluoroscopy times were substantially reduced, approaching half the time for HPSD than for LPLD. This study was also hypothesis generating: 1. A trend towards a reduction in blanking period arrhythmias was noted in the HPSD group and appears to be consistent with other studies. Given that the absolute time required for catheter stability is shorter with HPSD ablation, this may have led to a higher proportion of RF lesions causing *irreversible* injury as compared to LPLD ablation accounting for this observation. It is also interesting that LPLD was associated with a higher rate of early recurrence of AF, and further research would be required to determine whether this might be related to a greater inflammatory response due to lower power ablation lesions. 2. There were numerically but not statistically significant lower numbers of repeat ablation procedures in the HPSD group. Presumably a repeat ablation would have been performed in the presence of symptom recurrence or new persistent AF.

A lower number of repeat ablations in the HPSD group would therefore suggest improved clinically meaningful long-term durability as compared to LPLD. Longer follow-up would be necessary to determine a difference.

The overall success rates of PVI for paroxysmal AF range from 60-80% after a single procedure. Despite the advent of irrigated and contact force sensing catheters, PV reconnection occurs in 22% of PVs acutely and 15% of PVs 3 months after isolation ^{15,16}. Attempts to improve clinical outcomes have targeted the efficacy of lesion formation including a focus on catheter stability with steerable sheaths, atrial or ventricular pacing, and low-tidal volume ventilation settings/high-frequency jet ventilation ¹⁷. The adoption of real time lesion surrogates such as AI and LSI to demonstrate lesion quality have also advanced the field. The 'CLOSE'-guided PVI protocol with an ILD of 6mm with a target AI of 400 posteriorly and 550 anteriorly was proposed and validated, demonstrating long-term durability with a single-procedure freedom from any atrial arrhythmia of 87% at 1 year and 78% at 2 years on no antiarrhythmic therapy ¹⁸. Additional electrogram (egm) monitoring beyond the 'close'-guided PVI suggested to be of limited value based on characterization of real-time changes in bipolar and unipolar egms ¹⁹.

Based on the premise of wider lesion size with shorter energy delivery times, a HPSD strategy had the promise of even further improved outcomes. Irrigated catheters allowed for application of higher powers without the creation of steam pops; irrigation with 17ml/min allowed delivery of higher powers of 40 W up to 30 seconds as compared to 10 seconds with a lower irrigation flow at 2ml/min ²⁰. Initial *in vitro* and *in vivo* ovine models compared standard settings of 40 W/30 sec with a temperature limit of 50 deg C with 40, 50, 60, 70, and 80 W for 5 second duration with

saline irrigation set at 30ml/min². Compared with conventional settings, 50 and 60 W for 5 seconds achieved transmurality and was safer (steam pops were absent with HPSD ablations). Operators have investigated AI-guided PVI with different power protocols including 50 W anterior/40 W posterior, 40 W anterior/30 W posterior, and 30 W anterior/20 W posterior with the same target AI (400 anteriorly, 360 posteriorly and 260 on the esophagus)²¹. Higher power applications significantly increased the first-pass isolation rate (85%, 80%, and 55% respectively), but no significant difference was noted in the AF-free survival rates at 6 months. Yavin et al compared 112 patients undergoing HPSD ablations to historical controls undergoing standard ablation ⁵. A higher acute success was seen with HPSD ablation (90.2% vs 83%, p=0.06) with shorter ablation times (17.2 +- 3.4 minutes vs 31.1 +- 5.6 minutes, p<0.001) and a lower incidence of chronic PV reconnections (16.6% vs 52.2%, p=0.03). Interestingly, in a higher proportion of HPSD applications, catheter motion was <1mm during 50% or more of the application duration, thereby improving stability during lesion delivery. Chen *et al* reported on their series of 122 consecutive patients undergoing HPSD ablation with 50 W targeting an AI of 550 anteriorly and 400 posteriorly with an ILD of 6mm²². First-pass isolation was noted in 96.7%. Follow-up with 72hour holters demonstrated a single-procedure freedom from clinical recurrence of atrial arrhythmia off antiarrhythmic drug of 85.2% (89% for paroxysmal AF and 80% for persistent AF) at 15 months. The mean contact force, RF duration, AI, and impedance drop at the anterior/posterior wall were $26 \pm 14g/23 \pm 12g$, $16.2 \pm 7.5s/8.8 \pm 3.6s$, $552 \pm 53/438 \pm 47$, and $13 \pm 6\Omega/9 \pm 5\Omega$. Finally, a recent meta-analysis using a HPSD definition of > 40 W with ablation duration of 2-10 sec per site identified 6 prospective studies, 3 retrospective, and 1 randomized controlled trial. In 2467 patients, pooled analyses demonstrated higher rates of first-pass isolation than LPLD ablation (RR 1.2 [95% CI, 1.1-1.31]; P<0.001) and a reduction in atrial arrhythmia recurrence (RR 0.73 [95%

CI, 0.58-0.91]; P=0.005) ²³. Major complications and esophageal thermal injury were similar between groups.

Atrio-esophageal fistula as a consequence of LA ablation remains rare but devastating. Given that HPSD creates broader and shallower lesions with less conductive heating ²⁴, it follows that a theoretical advantage may be a lower risk of atrio-esophageal fistula. In cadaver studies, the mean (min, max) LA transmural thickness at the anterior wall, roof, and posterior wall was found to be $1.86 \pm 0.59 \text{ mm} (0.6, 2.6), 1.06 \pm 0.49 \text{ mm} (0.8, 1.51), \text{ and } 1.4 \pm 0.46 \text{ mm} (0.9, 2).$ Although a formalin effect appeared to influence the posterior wall measurements ²⁵ these thicknesses correlated with measurements on computational tomography ²⁶. The LA wall has also been reported to be thinner in patients with AF compared with those without ²⁷. Other studies have revealed that the esophageal wall was <5mm from the endocardium in 40% of patients, and that the LA thickness differed significantly among several different regions of the posterior wall ²⁸. Using same-day late gadolinium enhancement magnetic resonance imaging, moderate-to-severe esophageal enhancement was seen in 14.3% of patients undergoing AF ablation with both HPSD (50W/5s) and LPLD (<35W for 10-30 seconds).

HPSD has demonstrated clinical safety in our as well as in several other studies. Winkle *et al.* demonstrated posterior wall applications using 45-50 W for 2-10 seconds to be safe ⁹. In a study including 10,284 patients from four centers, one atrioesophageal fistula (0.0087%) occurred in 11,436 HPSD ablations performed using 45-50 W for 2-10 seconds on the posterior wall, while three atrioesophageal fistulas (0.12%) occurred in 2538 LPLD ablations using 35 W on the posterior wall for 20 seconds (p=0.021) ¹⁰. Notably, two of the three fistulas in the LPLD group did not undergo esophageal temperature monitoring. A strategy of HPSD with 45 W vs LPLD with

35 W using the 'close' protocol was evaluated in a prospective, randomized controlled study involving a total of 100 patients ²⁹. Endoscopic evaluation performed in a proportion of patients revealed the presence of an ulcerative perforation in the HPSD group which required endoscopic stenting with normalization after 4 months. A superficial ulcerative lesion in a control group patient was treated conservatively, however both occurred following excessive AI applications (up to 460 and 480 respectively) with excessive contact force (average 30 g with peaks up to 50g). Finally, in another study of 122 patients undergoing HPSD ablation, patients with an esophageal temperature of \geq 39 degrees C underwent post-ablation endoscopy. Three (2.5%) patients had asymptomatic endoscopic small erosion/erythema esophageal lesions with no serious adverse events observed ³⁰.

This study represented a substudy of a randomized controlled trial with standardized protocols and uniform follow-up however the allocation of HPSD vs LPLD was not randomized and was according to operator preference. Data on the duration of the recurrent atrial arrhythmia or the presence or absence of symptoms during AF episodes during follow-up were not collected. This prevented understanding the indication to proceed with a repeat intervention or determine if the type of recurrence was clinically relevant. Data on first-pass isolation was not collected.

In this substudy of the AWARE trial, a HPSD ablation approach was found to be associated with a marked reduction in procedural duration and fluoroscopy time, while being similarly effective as a LPLD approach for the incidence of recurrent atrial arrhythmia post ablation for paroxysmal AF. A numerically lower number of blanking period arrhythmias were noted with

HPSD with trends towards lower repeat ablations. Further studies with longer follow-up are necessary to confirm these findings.

Acknowledgements: none

Sources of Funding:

The AWARE RCT was funded by grants from the Canadian Institutes of Health Research, the University of Ottawa Heart Institute, Division of Cardiology and Academic Medical Organization, and by an unrestricted research grant from Biosense Webster (IIS-381). Dr. Essebag is supported by a Clinical Research Scholar Award from the Fonds de Recherche du Quebec Santé (FRQS).

Disclosures: Dr. Jacqueline Joza reports investigator-initiated external grant support from
Medtronic Inc. and consulting fees from Boston Scientific (Modest) and honoraria from Biosense
Webster Canada (Modest). Dr. Girish M. Nair reports honoraria, speaking fees and grant
support from Biosense Webster Inc. and Boston Scientific Inc. related to Atrial Fibrillation
(Modest). Dr. Pablo B. Nery reports honoraria, speaking fees and grant support from Biosense
Webstern Canada, not related to this work (Modest). Dr. David H. Birnie reports grants from
Boehringer Ingelheim, Germany, grants from Pfizer and Bristol-Myers Squibb, New York
(Modest). Dr. George Veenhuyzen has received honoraria & consulting fees from Medtronic,
BMS-Pfizer, Servier, & Biotronik. Dr. Jean-Francois Sarrazin has received consulting fees
from Biosense Webster. Dr. Jean-Francois Roux has received consulting feeds from Biosense
Webster, Boston Scientific, and Medtronic for AF related lectures and research support. Dr.
Ratika Parkash has received consulting fees/honoraria and research support from Abbott,

Biosense Webster and Medtronic Inc. **Dr. John Sapp** has received honoraria from Biosense Webster Inc., Abbott Inc., Medtronic Inc., and Varian Inc. He has also received research grants from Biosense Webster Inc., and Abbott Inc. **Dr. Laurence D. Sterns** has received honoraria from Biosense Webster Inc., **Dr. Vijay S. Chauhan** has received consulting fees/honoraria and research support from Biosense Webster Inc. **Dr. Vidal Essebag** has received honoraria from Abbott, Biosense Webster, Boston Scientific, and Medtronic. The other authors have no disclosures related to this publication.

References

- 1. Kotadia ID, Williams SE, O'Neill M. High-power, Short-duration Radiofrequency Ablation for the Treatment of AF. *Arrhythm Electrophysiol Rev.* 2020;8:265-272. doi: 10.15420/aer.2019.09
- 2. Bhaskaran A, Chik W, Pouliopoulos J, Nalliah C, Qian P, Barry T, Nadri F, Samanta R, Tran Y, Thomas S, et al. Five seconds of 50-60 W radio frequency atrial ablations were transmural and safe: an in vitro mechanistic assessment and force-controlled in vivo validation. *Europace*. 2017;19:874-880. doi: 10.1093/europace/euw077
- 3. Naniwadekar A, Dukkipati SR. High-power short-duration ablation of atrial fibrillation: A contemporary review. *Pacing Clin Electrophysiol*. 2021;44:528-540. doi: 10.1111/pace.14167
- Leshem E, Zilberman I, Tschabrunn CM, Barkagan M, Contreras-Valdes FM, Govari A, Anter E. High-Power and Short-Duration Ablation for Pulmonary Vein Isolation: Biophysical Characterization. *JACC Clin Electrophysiol*. 2018;4:467-479. doi: 10.1016/j.jacep.2017.11.018
- Yavin HD, Leshem E, Shapira-Daniels A, Sroubek J, Barkagan M, Haffajee CI, Cooper JM, Anter E. Impact of High-Power Short-Duration Radiofrequency Ablation on Long-Term Lesion Durability for Atrial Fibrillation Ablation. *JACC Clin Electrophysiol*. 2020;6:973-985. doi: 10.1016/j.jacep.2020.04.023
- 6. Reddy VY, Grimaldi M, De Potter T, Vijgen JM, Bulava A, Duytschaever MF, Martinek M, Natale A, Knecht S, Neuzil P, et al. Pulmonary Vein Isolation With Very High Power, Short Duration, Temperature-Controlled Lesions: The QDOT-FAST Trial. *JACC Clin Electrophysiol*. 2019;5:778-786. doi: 10.1016/j.jacep.2019.04.009
- 7. Kottmaier M, Popa M, Bourier F, Reents T, Cifuentes J, Semmler V, Telishevska M, Otgonbayar U, Koch-Buttner K, Lennerz C, et al. Safety and outcome of very high-power short-duration ablation using 70 W for pulmonary vein isolation in patients with paroxysmal atrial fibrillation. *Europace*. 2020;22:388-393. doi: 10.1093/europace/euz342
- Baher A, Kheirkhahan M, Rechenmacher SJ, Marashly Q, Kholmovski EG, Siebermair J, Acharya M, Aljuaid M, Morris AK, Kaur G, et al. High-Power Radiofrequency Catheter Ablation of Atrial Fibrillation: Using Late Gadolinium Enhancement Magnetic Resonance Imaging as a Novel Index of Esophageal Injury. *JACC Clin Electrophysiol*. 2018;4:1583-1594. doi: 10.1016/j.jacep.2018.07.017
- 9. Winkle RA, Mohanty S, Patrawala RA, Mead RH, Kong MH, Engel G, Salcedo J, Trivedi CG, Gianni C, Jais P, et al. Low complication rates using high power (45-50 W) for short duration for atrial fibrillation ablations. *Heart Rhythm*. 2019;16:165-169. doi: 10.1016/j.hrthm.2018.11.031
- Vassallo F, Cunha C, Serpa E, Meigre LL, Carloni H, Simoes A, Jr., Hespanhol D, Lovatto CV, Batista W, Jr., Serpa R. Comparison of high-power short-duration (HPSD) ablation of atrial fibrillation using a contact force-sensing catheter and conventional technique: Initial results. *J Cardiovasc Electrophysiol*. 2019;30:1877-1883. doi: 10.1111/jce.14110

- 11. Nair GM, Birnie DH, Nery PB, Redpath CJ, Sarrazin JF, Roux JF, Parkash R, Bernier M, Sterns LD, Sapp J, et al. Standard vs Augmented Ablation of Paroxysmal Atrial Fibrillation for Reduction of Atrial Fibrillation Recurrence: The AWARE Randomized Clinical Trial. *JAMA Cardiol*. 2023. doi: 10.1001/jamacardio.2023.0212
- 12. Nair GM, Birnie DH, Wells GA, Nery PB, Redpath CJ, Sarrazin JF, Roux JF, Parkash R, Bernier M, Sterns LD, et al. Augmented wide area circumferential catheter ablation for reduction of atrial fibrillation recurrence (AWARE) trial: Design and rationale. *Am Heart J*. 2022;248:1-12. doi: 10.1016/j.ahj.2022.02.009
- 13. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. *Stat Med.* 2009;28:3083-3107. doi: 10.1002/sim.3697
- 14. Zou G. A modified poisson regression approach to prospective studies with binary data. *Am J Epidemiol*. 2004;159:702-706. doi: 10.1093/aje/kwh090
- Kautzner J, Neuzil P, Lambert H, Peichl P, Petru J, Cihak R, Skoda J, Wichterle D, Wissner E, Yulzari A, et al. EFFICAS II: optimization of catheter contact force improves outcome of pulmonary vein isolation for paroxysmal atrial fibrillation. *Europace*. 2015;17:1229-1235. doi: 10.1093/europace/euv057
- 16. Ullah W, McLean A, Tayebjee MH, Gupta D, Ginks MR, Haywood GA, O'Neill M, Lambiase PD, Earley MJ, Schilling RJ, et al. Randomized trial comparing pulmonary vein isolation using the SmartTouch catheter with or without real-time contact force data. *Heart Rhythm.* 2016;13:1761-1767. doi: 10.1016/j.hrthm.2016.05.011
- 17. Aizer A, Qiu JK, Cheng AV, Wu PB, Barbhaiya CR, Jankelson L, Linton P, Bernstein SA, Park DS, Holmes DS, et al. Rapid pacing and high-frequency jet ventilation additively improve catheter stability during atrial fibrillation ablation. *J Cardiovasc Electrophysiol.* 2020;31:1678-1686. doi: 10.1111/jce.14507
- Duytschaever M, De Pooter J, Demolder A, El Haddad M, Phlips T, Strisciuglio T, Debonnaire P, Wolf M, Vandekerckhove Y, Knecht S, et al. Long-term impact of catheter ablation on arrhythmia burden in low-risk patients with paroxysmal atrial fibrillation: The CLOSE to CURE study. *Heart Rhythm*. 2020;17:535-543. doi: 10.1016/j.hrthm.2019.11.004
- 19. Coeman M, Haddad ME, Wol M, Choudhury R, Vandekerckhove Y, Choudhury R, Knecht S, Tavernier R, Duytschaever M. 'CLOSE'-Guided Pulmonary Vein Isolation and Changes in Local Bipolar and Unipolar Atrial Electrograms: Observations from the EP Lab. *J Atr Fibrillation*. 2018;10:1794. doi: 10.4022/jafib.1794
- 20. Ali-Ahmed F, Goyal V, Patel M, Orelaru F, Haines DE, Wong WS. High-power, lowflow, short-ablation duration-the key to avoid collateral injury? *J Interv Card Electrophysiol*. 2019;55:9-16. doi: 10.1007/s10840-018-0473-5
- 21. Okamatsu H, Koyama J, Sakai Y, Negishi K, Hayashi K, Tsurugi T, Tanaka Y, Nakao K, Sakamoto T, Okumura K. High-power application is associated with shorter procedure time and higher rate of first-pass pulmonary vein isolation in ablation index-guided atrial fibrillation ablation. *J Cardiovasc Electrophysiol*. 2019;30:2751-2758. doi: 10.1111/jce.14223
- Chen S, Schmidt B, Bordignon S, Tohoku S, Urban VC, Schulte-Hahn B, Chun KRJ.
 Catheter ablation of atrial fibrillation using ablation index-guided high-power technique: Frankfurt AI high-power 15-month follow-up. *J Cardiovasc Electrophysiol*. 2021;32:616-624. doi: 10.1111/jce.14912

- Chen CF, Wu J, Jin CL, Liu MJ, Xu YZ. Comparison of high-power short-duration and low-power long-duration radiofrequency ablation for treating atrial fibrillation: Systematic review and meta-analysis. *Clin Cardiol.* 2020;43:1631-1640. doi: 10.1002/clc.23493
- 24. Winkle RA. HPSD ablation for AF high-power short-duration RF ablation for atrial fibrillation: A review. *J Cardiovasc Electrophysiol*. 2021;32:2813-2823. doi: 10.1111/jce.14863
- 25. Hall B, Jeevanantham V, Simon R, Filippone J, Vorobiof G, Daubert J. Variation in left atrial transmural wall thickness at sites commonly targeted for ablation of atrial fibrillation. *J Interv Card Electrophysiol*. 2006;17:127-132. doi: 10.1007/s10840-006-9052-2
- 26. Beinart R, Abbara S, Blum A, Ferencik M, Heist K, Ruskin J, Mansour M. Left atrial wall thickness variability measured by CT scans in patients undergoing pulmonary vein isolation. *J Cardiovasc Electrophysiol*. 2011;22:1232-1236. doi: 10.1111/j.1540-8167.2011.02100.x
- 27. Nakamura K, Funabashi N, Uehara M, Ueda M, Murayama T, Takaoka H, Komuro I. Left atrial wall thickness in paroxysmal atrial fibrillation by multislice-CT is initial marker of structural remodeling and predictor of transition from paroxysmal to chronic form. *Int J Cardiol.* 2011;148:139-147. doi: 10.1016/j.ijcard.2009.10.032
- 28. Sanchez-Quintana D, Cabrera JA, Climent V, Farre J, Mendonca MC, Ho SY. Anatomic relations between the esophagus and left atrium and relevance for ablation of atrial fibrillation. *Circulation*. 2005;112:1400-1405. doi: 10.1161/CIRCULATIONAHA.105.551291
- 29. Wielandts JY, Kyriakopoulou M, Almorad A, Hilfiker G, Strisciuglio T, Phlips T, El Haddad M, Lycke M, Unger P, Le Polain de Waroux JB, et al. Prospective Randomized Evaluation of High Power During CLOSE-Guided Pulmonary Vein Isolation: The POWER-AF Study. *Circ Arrhythm Electrophysiol*. 2021;14:e009112. doi: 10.1161/CIRCEP.120.009112
- 30. Chen S, Chun KRJ, Tohoku S, Bordignon S, Urbanek L, Willems F, Plank K, Hilbert M, Konstantinou A, Tsianakas N, et al. Esophageal Endoscopy After Catheter Ablation of Atrial Fibrillation Using Ablation-Index Guided High-Power: Frankfurt AI-HP ESO-I. *JACC Clin Electrophysiol*. 2020;6:1253-1261. doi: 10.1016/j.jacep.2020.05.022

	LPLD Group	HPSD Group	Absolute Standardized	
	N=225	N=173	Difference	
			Unadjusted	Adjusted*
Age (years)	60.10 ± 9.46	62.20 ± 8.99	0.228	0.021
Sex	62(27.6%)	69(39.9%)	0.263	0.010
BMI (Kg/m ²)	28.86±5.33	29.36±6.01	0.088	0.020
CIED	2(0.89%)	3(1.73%)	0.074	0.017
Time since	54.69± 59.41	50.93±65.59	0.060	0.015
diagnosis (months)				
CHF	6(2.7%)	5(2.9%)	0.013	0.021
Hypertension	83(36.9%)	82(47.4%)	0.214	0.021
Diabetes Mellitus	19(8.4%)	21(12.2%)	0.122	0.008
Prior History of	14(6.2%)	13(7.5%)	0.051	0.010
Stroke/TIA or				
thromboembolism				
CHADS-65 Score				
CHA2DS2-VASc	1.30 ± 1.25	1.75 ± 1.35	0.346	0.011
score				
Antiarrhythmic				
Propafenone	16(7.11%)	4(2.31%)	0.228	0.085
Flecainide	56(24.9%)	44(25.4%)	0.012	0.020
Sotalol	22(9.8%)	18(10.4%)	0.021	0.014
Amiodarone	32(14.2%)	29(16.8%)	0.070	< 0.001
Dronedarone	3(1.33%)	3(1.73%)	0.033	0.002
No antiarrhythmic	96(42.7%)	75(43.4%)	0.014	0.044
medications				
ACE-Inhibitors	35(15.6%)	27(15.6%)	0.001	0.006
ARB	16(7.1%)	19(19.9%)	0.383	0.004
Beta-blockers	106(47.1%)	82(47.4%)	0.006	0.033
Diltiazem/Verapamil	35(15.6%)	29(16.7%)	0.033	0.009
Digoxin	2(0.89%)	4(2.31%)	0.113	0.031
Aspirin/antiplatelet	36(16.0%)	10(5.8%)	0.333	0.097
agents				
Statins	64(28.4%)	71(41.0%)	0.267	0.025
Anticoagulants				
No systemic	32(14.2%)	38(21.0%)	0.202	0.055
anticoagulation prior	. ,			
to enrolment				
Warfarin	5(2.22%)	2(1.16%)	0.082	0.017

Table 1. Baseline characteristics: Comparison of the low-power long duration (LPLD) and high-power short duration (HPSD) ablation strategies

Dabigatran	18(8.0%)	4(2.31%)	0.259	0.026
Rivaroxaban	91(40.44%)	54(31.21%)	0.193	0.002
Apixaban	76(33.78%)	65(37.57%)	0.079	0.036
Edoxaban	3(1.33%)	10(5.78%)	0.242	0.026
Left atrial diameter	41.93 ± 35.03	41.78 ± 33.51	0.013	0.020
(mm)	N=147	N=98		
LAVI (ml/m ²)	32.88 ± 10.17	33.12 ± 10.06	0.024	0.004
	N=160	N=115		

*Adjusted using propensity scores with inverse probability treatment weighting

Legend: Plus-minus values are provided as mean \pm SD and other data presented as number (percentage). AAD = antiarrhythmic drug; ACE= angiotensin-converting enzyme; AF=atrial fibrillation; ARB=Angiotensin receptor blocker; BMI= body mass index (weight in kilograms divided by square of the height in meters); CHF=congestive heart failure (New York Heart Association Heart Failure class II or Left ventricular ejection fraction < 50%); CIED= cardiac implantable electronic device; LA=left atrium; LAVI= Left atrial volume index; TIA=transient ischemic attack.

Table 2. Primary and secondary clinical and procedural outcomes: Comparison of the low-power long duration (LPLD) and high-power short duration (HPSD) ablation strategies

Outcome	LPLD Group	HPSD Group	RR _a (95% CI)	p-value
Primary Outcome: 1 year	11-223	N-175		
recurrence rate of any ECG	50 (22.2%)	52 (30.1%)	0.77 (0.55 1.10)	0.165
documented AF AFL or AT	30 (22.270)	52 (50.170)	0.77(0.33-1.10)	0.105
(symptomatic or asymptomatic:				
asting > 30 seconds occurring 91				
days or more after catheter				
ablation				
Secondary arrhythmia				
outcomes:				
i. Need for repeat catheter	22 (9.8%)	12 (6.9%)	1.59 (0.77-3.30)	0.208
ablation procedure because				
of documented recurrence				
of symptomatic AF, AFl or				
AT				
ii. Incidence of any ECG				
documented AF	18 (8.0%)	3 (1.7%)	3.95 (1.00-5.61)	0.049
(symptomatic or				
asymptomatic) during the				
first 90 days after catheter				
ablation				
Atrial arrhythmia in blanking	8	2	†	†
period (<91 days) predicting	(44.4%)	(66.7%)		
primary outcome	N=18	N=3		
Secondary procedural outcomes				
i. Total procedure duration	254 5+72 54	152 3+57 24	97 5 (84 6-110 4)*	< 0001
(sec): mean+sd	201.0272.01	102.0207.21	71.5 (04.0-110.4)	
(See). mean_se				
ii. Total fluoroscopic exposure	20.8+ 22.36	9.9±7.58	10.0 (6.7-13.3)*	
(min): mean+sd	20102 22100		10.0 (0.7 15.5)	<.0001
()·				
Secondary health care				
utilization outcomes				
i. Need for emergency	50	36	1.07 (0.72-1.61)	0.746
department visit	(22.2%)	(20.8%)		
_			1.25 (0.67-2.31)	
ii. Hospitalizations related to	26	17		0.482
atrial arrhythmias/procedure	(11.6%)	(9.8%)		
Hospital and ED visit	64	45	1.08 (0.76-1.53)	0.674
composite	(28.4%)	(26%)		

ED visit for atrial arrhythmia	18	14	1.16 (0.61-2.20)	0.643
_	(8.00 %)	(8.09%)		
Hospital visit for atrial	(3.11%)	6	1.24 (0.38-4.01)	0.716
arrhythmia		(3.47%)		
Hospital or ED visit for atrial	24	17	1.16 (0.61-2.20)	0.643
arrhythmia composite	(10.67%)	(9.83%)		
ED visit for atrial arrhythmia	14	10	1.02 (0.44-2.34)	0.963
after 90 days	(6.22%)	(5.78%)		
Hospital visit for atrial	5	5	1.05(0.26-3.90)	0.994
arrhythmia after 90 days	(2.22%)	(2.89%)		
Hospital or ED visit for atrial	18	13	1.05 (0.50-2.19)	0.895
arrhythmia composite after 90	(8.00%)	(7.51%)		
days				

Legend: Plus-minus values are provided as mean \pm SD and other data presented as number (percentage). AF= atrial fibrillation; AFl=atrial flutter; AT=atrial tachycardia; EQ-5D= European Quality of Life 5 day score; PVI=pulmonary vein isolation; CCS= Canadian Cardiovascular Society; TIA=transient ischemic attack; Conventional WACA=wide area circumferential ablation to achieve PVI; Augmented WACA=double WACA lesion set to achieve PVI; QoL=quality of life; * Adjusted MD_a least squares mean difference and 95% CI; † data too sparse for a formal statistical analysis

Subgroup	N	RRa	Interaction p-value
			0.9608
Male	267	0.77 (0.48-1.24)	
Female	131	0.79 (0.46-1.34)	
			0.3067
$Age \le 65$	248	0.67 (0.40-1.09)	
Age > 65	150	0.95 (0.58-1.54)	
			0.0272
Duration of AF <50 months	268	0.69 (0.39-0.93)	
Duration of $AF \ge 50$ months	130	1.49 (0.76-2.94)	
			0.2841
No CHF	387	0.75 (0.52-1.08)	
CHF	11	1.57 (0.42-5.76)	
			0.0291
No Hypertension	233	0.55 (0.33-0.88)	
Hypertension	165	1.18 (0.71-1.95)	
			0.4525
No Diabetes	358	0.82 (0.56-1.20)	
Diabetes	40	0.53 (0.18-1.54)	
			0.1220
No Stroke history	371	0.82 (0.57-1.18)	
Stroke history	27	0.15 (0.02-1.25)	
			0.2148
$CHA_2DS_2VASc \ score < 4$	364	0.72 (0.49-1.06)	
$CHA_2DS_2VASc \text{ score } \geq 4$	34	1.27 (0.56-2.88)	
			0.2597
Single WACA arm	195	0.64 (0.39-1.05)	
Double WACA arm	203	0.97 (0.58-1.61)	

Table 3. One-year recurrence rate: Comparison of the low-power long duration (LPLD) and high-power short duration (HPSD) ablation strategies by subgroups

Table 4. Serious adverse events: Comparison of the low-power long duration (LPLD) and high-power short duration (HPSD) ablation strategies

Serious Adverse Events	LPLD Group N=225	HPSD Group N=173
	n (%)	n (%)
Death	0	0
Atrial Fibrillation	3 (1.33%)	0
Atrial Flutter	1 (0.44%)	1 (0.58%)
Congestive Heart Failure	2 (0.89%)	1 (0.58%)

Sinus bradycardia	0	1(0.58%)
Ischemic Stroke	0	0
Transient ischemic attack	0	0
Major Bleeding (requiring transfusion)	1 (0.44%)	0
Minor Bleeding	2 (0.89 %)	0
Hypotension	1 (0.44%)	0
Pneumonia	1 (0.44%)	0
Pseudonaneurysm	1 (0.44%)	1 (0.58%)
Arterio-venous Fistula	1 (0.44%)	0
Cardiac Perforation (with tamponade)	2 (0.89%)	0
Pericarditis	0	1 (0.58%)
Pulmonary Vein Stenosis	0	1 (0.58%)
Diaphragmatic paralysis	0	0
Esophageal ulcer perforation	1 (0.44%)	0

A serious adverse event was defined as an adverse event that led to death; that led to a serious deterioration in health resulting in a life-threatening illness or injury, permanent impairment of a body structure or a body function, inpatient hospitalization, prolonged hospitalization (>24 hours), or medical or surgical experiment to prevent life-threatening illness, injury, or permanent impairment to a body structure or a body function; or that led to fetal distress, fetal death, or a congenital abnormality or birth defect.



Graphical Abstract